Official Title: “the Therapeutic Effect Treated With Tamsulosin After ESWL in Urinary Calculus”

The purpose of this study is to compare the stone clearance rate treated with different drugs after ESWL in urinary calculus,These drugs are often used in urinary calculus,such as progesterone,tamsulosin,propantheline Bromide and nifedipine.In these study the investigators want to investigate different effect of these drugs use to treat urinary calculus after ESWL.

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Outcomes Assessor), Dose Comparison, Parallel Assignment, Bio-equivalence Study

Study Primary Completion Date: October 2009

There is 4 groups in these investigation, group1 urinary calculus treated with ESWL only ,group2 urinary calculus treated with ESWL and tamsulosin,group3 urinary calculus treated with ESWL and progesterone,group4 urinary calculus treated with ESWL ,propantheline Bromide and nifedipine.We want to investigate which one is better or not in urinary calculus treated with ESWL .

Intervention(s) in this Clinical Trial

• Drug: progesterone,tamsulosin,propantheline Bromide and nifedipine
  • clearance rate of stone

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: progesterone,tamsulosin,propantheline Bromide and nifedipine
  • different effect of these drugs use to treat urinary calculus after ESWL

Primary Measures

• different effect of these drugs use to treat urinary calculus after ESWL
  • Time Frame: 2weeks
    Safety Issue?: Yes

Inclusion Criteria:

• From 18 years old to 68 years old,
• urinary calculus could be treated by ESWL,
• the calculus size is from 4-25mm

Exclusion Criteria:

• Less than 18 years old or more than 68 years old,
• the calculus size is from Less than4 or larger than 25mm

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 68 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Lead Sponsor: Chongqing Medical University

Overall Clinical Trial Officials and Contacts

xiaohou wu, doctor Study Chair The first affiliated hospital, Chongqing medical university  

Overall Contact: Yunfeng He, Doctor 86-23-89011121 

Information obtained from ClinicalTrials.gov on February 04, 2010

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT01010048

Study ID Number: CQMU

ClinicalTrials.gov Identifier: NCT01010048

Health Authority: China: State Food and Drug Administration